盘点:8月5日Lancet研究精选

2017-08-08 zhangfan MedSci原创

8月5日Lancet研究精选



【1】CD30单抗用于T细胞淋巴增殖性疾病的治疗


研究发现表达于间变性大细胞淋巴瘤中的肿瘤坏死因子受体超家族的膜蛋白CD30是有效的T细胞淋巴增殖性疾病阳性的生物标志物。近日研究考察了CD30单克隆抗体SGN-30的治疗效果。研究发现,除了皮肤T淋巴细胞瘤,SGN-30对大部分T细胞淋巴增殖阳性疾病表现出良好的效果,23名患者中,16人出现完全应答应且答持续时间较为持久。

【2】预防腹壁切口疝——刻不容缓


腹壁切口疝是常见的术后并发症,影响患者生活质量并造成沉重的经济负担,据估计在美国,每减少1%的腹壁疝修补,将节约3200万美元的医疗支出。近日研究人员在PRIMA研究中考察了缝合方法对腹壁切口疝的预防效果,研究发现,接受一期缝合患者切口疝发生率为30%,内置网强化患者发病率为13%而补片修补内置网强化发病率为18%。内置网强化是有效的腹壁切口疝预防手段。

【3】中风后家庭康复治疗


在中低收入国家,由于人员以及设备的缺乏,中风幸存患者接受专业的康复训练十分困难。家庭康复训练可能是一种有效的替代方法。ATTEND研究考察了印度中风后家庭康复训练的效果。研究表明,接受家庭康复治疗的中风幸存者其死亡率略低于对照组(12% vs 14%),但在住院率以及非致死事件的发生率组间无显著差异。

【4】Brentuximab vedotin治疗CD30阳性皮肤T细胞淋巴瘤


近日研究人员公布了Brentuximab vedotin治疗CD30阳性皮肤T细胞淋巴瘤复发患者的III期临床研究结果。128名患者参与了数据分析,结果显示,在随访的22.9个月中,Brentuximab vedotin 治疗组56.3%的患者实现了至少4个月的客观缓解,而对照组仅为12.5%。组间不良事件率相近(41% vs 47%)。研究认为 Brentuximab vedotin的效果优于甲氨蝶呤或贝沙罗汀。

【5】关注青春期逆境损伤危害


因自残、药物、酒精以及暴力导致入院治疗的青年人群(逆境损伤)的持续心理辅导十分重要。近日研究人员考察了逆境相关损伤与青少年非正常死亡的关系。1997-2012年间,1080368名青少年参与研究,其中30.8%的青少年发生了逆境相关的损伤,而这些青少年中4782人(0.5%)在入院治疗后10年内死亡,青少年自杀、药物相关以及酒精相关的死亡风险提高3-4倍。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829133, encodeId=61f1182913379, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jul 12 09:13:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231950, encodeId=a71623195073, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 09 20:36:57 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231584, encodeId=3c0123158436, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Aug 08 19:21:54 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231548, encodeId=971c23154817, content=Brentuximabvedotin治疗CD30阳性皮肤T细胞淋巴瘤复发, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Tue Aug 08 16:48:10 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2018-07-12 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829133, encodeId=61f1182913379, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jul 12 09:13:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231950, encodeId=a71623195073, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 09 20:36:57 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231584, encodeId=3c0123158436, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Aug 08 19:21:54 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231548, encodeId=971c23154817, content=Brentuximabvedotin治疗CD30阳性皮肤T细胞淋巴瘤复发, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Tue Aug 08 16:48:10 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2017-08-09 luominglian113

    学习了,谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1829133, encodeId=61f1182913379, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jul 12 09:13:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231950, encodeId=a71623195073, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 09 20:36:57 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231584, encodeId=3c0123158436, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Aug 08 19:21:54 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231548, encodeId=971c23154817, content=Brentuximabvedotin治疗CD30阳性皮肤T细胞淋巴瘤复发, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Tue Aug 08 16:48:10 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2017-08-08 虈亣靌

    学习了新知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1829133, encodeId=61f1182913379, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jul 12 09:13:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231950, encodeId=a71623195073, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 09 20:36:57 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231584, encodeId=3c0123158436, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Aug 08 19:21:54 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231548, encodeId=971c23154817, content=Brentuximabvedotin治疗CD30阳性皮肤T细胞淋巴瘤复发, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Tue Aug 08 16:48:10 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2017-08-08 随梦飞扬

    Brentuximabvedotin治疗CD30阳性皮肤T细胞淋巴瘤复发

    0

相关资讯

盘点:7月18日Lancet子刊研究一览

7月18日Lancet子刊研究一览

盘点:7月29日Lancet研究一览

7月29日Lancet研究一览

盘点:Lancet杂志7月15日文章一览

Lancet杂志7月15日文章一览

盘点:2017年7月15日Lancet研究一览

2017年7月15日Lancet研究一览

盘点:2017年7月14日Lancet研究一览

2017年7月14日Lancet杂质研究一览

盘点:Lancet杂志7月22日研究一览

Lancet杂志7月22日研究一览